Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable Buprenorphine for Methamphetamine Use Disorder
NCT05283304Phase 2Terminated
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine in methamphetamine use disorder (MUD). Started Mar 2023; status: terminated.
02
Drugs
buprenorphine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT05283304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283304.